Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonavalent HPV Vaccine as Secondary Prevention in HSIL
NCT07431502Phase 3Not yet recruiting
- Sponsor
- Gustave Roussy
- Start
- May 2026
- Primary completion
- Nov 2030
- Modality
- Recombinant Protein Vaccines
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in Squamous Intraepithelial Lesion (SIL), sponsored by Gustave Roussy. Planned start May 2026; status: not yet recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
Squamous Intraepithelial Lesion (SIL)
Beyond the preview
Go deeper on NCT07431502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07431502.